Guidant Shines Light on Vulnerable Plaque with Miravant Deal

Guidant appears to be the leader among the large cardiovascular device companies in pursuing device-based therapies for vulnerable plaque. The company's latest move in this space is a collaboration with Miravant Medical Technologies regarding using photodynamic therapy as a possible treatment for vulnerable plaque lesions.

The one thing that cardiologists and cardiovascular device companies can agree on when it comes to vulnerable plaque (VP) is that it's too soon to know what they can agree on. But Guidant Corp. , perhaps chastened by its lagging efforts in drug-eluting stents, is not taking any chances on missing out on what some experts believe could be the next major cardiovascular device opportunity. The company appears to be the leader among the large cardiology device competitors in targeting vulnerable plaque, having begun its efforts in 1999.

Guidant's latest move in this space is a collaboration with Miravant Medical Technologies Inc. in an effort to investigate...

More from Innovation

More from In Vivo

Deals In Depth: June 2025

 
• By 

Five $1bn+ alliances were penned in June, and four exceeded $2bn.

Global Pharma Interest In Korea Undeterred Despite Political Roller Coaster

 
• By 

Despite recent political turmoil, outside investor and corporate interest in South Korean biopharma innovation appears robust or even increasing.

Podcast: Oxolife’s Agnés Arbat, Winner Of The European Prize For Women Innovators

 
• By 

Agnès Arbat, CEO of Oxolife and winner of the EU Women Innovators Prize, joins In Vivo to discuss OXO-001, a novel non-hormonal treatment aimed at improving embryo implantation in IVF. She shares insights from her biotech journey and the future of fertility innovation.